Reduction in the hepatitis B related burden of disease - measuring the success of universal immunisation programs
DOI:
https://doi.org/10.33321/cdi.2002.26.44Keywords:
hepatitis B, hepatitis serology, Vaccination, vaccination program, HBVAbstract
Infection with hepatitis B virus (HBV) continues to be an important cause of morbidity and mortality throughout the world. At present, there are approximately 350 million chronic HBV carriers worldwide, with rates ranging from country to country as well as within different regions of a country. For example, carrier rates are low among Caucasian populations in the United States of America (USA), Northern Europe and Australia (0.1-0.2%), but are much higher (up to 10%) in some Australian Aboriginal, Central African, and South-East Asian populations. Most east and South-East Asian and Middle Eastern countries have intermediate to high endemicity.
Downloads
References
Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13 Suppl 1:S47-49.
National Health and Medical Research Council. The Australian Immunisation Handbook, 7th ed. Canberra: Australian Government Publishing Service; 2000.
Ryder SD, Beckingham IJ. ABC of diseases of the liver, pancreas and biliary system: chronic viral hepatitis. BMJ 2001;322:219-221.
Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-352.
Goldstein ST, Fiore AE. Toward the global elimination of hepatitis B virus transmission. J Pediatr 2001;139:343-345.
Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994;44:144-151.
Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System. Paediatr Infect Dis J 1996;15:771-776.
Kane M. Status of hepatitis B immunization programmes in 1998. Vaccine 1998;16 Suppl:S104-108.
Hepatitis Control Report (online). 2001;6(3):Fall. Available from: www.hepatitiscontrolreport.com. Accessed 22 March 2002.
Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 1999;48:563-565.
Impact of the 1999 AAP/USPHS joint statement on Thimerosal in vaccines on infant hepatitis B vaccination practices. MMWR Morb Mortal Wkly Rep 2001;50:94-97.
Brayden RM, Pearson KA, Jones JS, Renfrew BL, Berman S. Effect of Thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies. J Paediatr 2001;138:752-755.
Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med J Aust 2000;173:403-405.
McIntyre P, Gidding H, Gilmour R, Hull B, Horby P, et al. Vaccine preventable diseases and vaccine coverage in Australia, 1999-2000. Commun Dis Intell 2002;26 Suppl:May.
Wexler DL. Needle tips and the hepatitis B coalition (online). Fall/Winter 2001-2002. Available from: www.immunize.org/nslt.d/n25/story25.htm. Accessed 22 March 2002.
Vryheid RE, Kane MA, Muller N, Schatz GC, Bezabeh S. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 2000;19:1026-1037.
Beutels P, Edmunds WJ, Antonanzas F, De Wit GA, Evans D, Feilden R, et al. Economic evaluation of vaccination programme: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002;20:1-7.
Betuels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001;10:751-774.
Aschiero A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-332.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2002 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
